Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study.
Marconcini R, Fava P, Nuzzo A, Manacorda S, Ferrari M, De Rosa F, De Tursi M, Tanda ET, Consoli F, Minisini A, Pimpinelli N, Morgese F, Bersanelli M, Tucci M, Saponara M, Parisi A, Ocelli M, Bazzurri S, Massaro G, Morganti R, Ciardetti I, Stanganelli I. Marconcini R, et al. Among authors: fava p. Front Oncol. 2022 Aug 15;12:917999. doi: 10.3389/fonc.2022.917999. eCollection 2022. Front Oncol. 2022. PMID: 36046043 Free PMC article.
Mogamulizumab associated crusted scabies: a rare diagnostic confounder.
Giunipero DI Corteranzo I, Roccuzzo G, Crespi O, Cavaliere G, Fava P, Ribero S, Quaglino P. Giunipero DI Corteranzo I, et al. Among authors: fava p. Ital J Dermatol Venerol. 2024 Aug;159(4):470-472. doi: 10.23736/S2784-8671.24.07953-2. Epub 2024 Jun 5. Ital J Dermatol Venerol. 2024. PMID: 38842065 No abstract available.
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.
Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, Leo C, Carosio R, Laurent S, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Battaglia A, Ascierto PA, Capone M, Simeone E, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Mandalà M, Merelli B, Quaglino P, Fava P, Guidoboni M, Romani M, Spagnolo F, Pistillo MP. Queirolo P, et al. Among authors: fava c, fava p. Front Immunol. 2017 Apr 12;8:386. doi: 10.3389/fimmu.2017.00386. eCollection 2017. Front Immunol. 2017. PMID: 28446908 Free PMC article.
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study.
Pistillo MP, Fontana V, Morabito A, Dozin B, Laurent S, Carosio R, Banelli B, Ferrero F, Spano L, Tanda E, Ferrucci PF, Martinoli C, Cocorocchio E, Guida M, Tommasi S, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Quaglino P, Fava P, Osella-Abate S, Ascierto PA, Capone M, Simeone E, Romani M, Spagnolo F, Queirolo P; Italian Melanoma Intergroup (IMI). Pistillo MP, et al. Among authors: fava p. Cancer Immunol Immunother. 2019 Jan;68(1):97-107. doi: 10.1007/s00262-018-2258-1. Epub 2018 Oct 11. Cancer Immunol Immunother. 2019. PMID: 30311027 Free PMC article.
Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19.
Pala L, Conforti F, Saponara M, De Pas T, Giugliano F, Omodeo Salè E, Jemos C, Rubatto M, Agostini A, Quaglino P, Fava P, Fierro MT, Queirolo P. Pala L, et al. Among authors: fava p. Semin Oncol. 2020 Oct;47(5):302-304. doi: 10.1053/j.seminoncol.2020.07.010. Epub 2020 Aug 7. Semin Oncol. 2020. PMID: 32883537 Free PMC article.
Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy).
Aglietta M, Chiarion-Sileni V, Fava P, Guidoboni M, Depenni R, Minisini A, Consoli F, Ascierto P, Rinaldi G, Banzi M, Marconcini R, Gueli R, Ferraresi V, Tucci M, Tonini G, Lo Re G, Guida M, Del Vecchio M, Marcon IG, Queirolo P. Aglietta M, et al. Among authors: fava p. Target Oncol. 2021 Nov;16(6):789-799. doi: 10.1007/s11523-021-00850-1. Epub 2021 Nov 10. Target Oncol. 2021. PMID: 34755244 Free PMC article.
Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study.
Gullo G, Rubatto M, Fava P, Brizio M, Tonella L, Ribero S, Medri M, Avallone G, Mastorino L, Fierro MT, Stanganelli I, Quaglino P. Gullo G, et al. Among authors: fava p. Dermatol Ther. 2022 Jun;35(6):e15492. doi: 10.1111/dth.15492. Epub 2022 May 10. Dermatol Ther. 2022. PMID: 35384181 Free PMC article.
Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
Boutros A, Bottini A, Rossi G, Tanda ET, Spagnolo F, Barletta G, Croce E, Fava P, Parisi A, De Rosa F, Palla M, Marconcini R, Ferrari M, Grandis M, Spallarossa P, Sarocchi M, Arboscello E, Del Mastro L, Lambertini M, Pronzato P, Genova C. Boutros A, et al. Among authors: fava p. ESMO Open. 2023 Feb;8(1):100791. doi: 10.1016/j.esmoop.2023.100791. Epub 2023 Feb 13. ESMO Open. 2023. PMID: 36791639 Free PMC article.
158 results